口服索马托他因子受体连接体是否越来越接近成为现实?
David S McLaren1,2, Nikolaos Kyriakakis1, Khyatisha Seejore1
1Departments of Endocrinology, Leeds Centre for Diabetes & Endocrinology, Leeds Teaching Hospital NHS Trust, Leeds, UK.
Clinical endocrinology
|December 31, 2024
概括
可注射的索马托斯塔丁受体连接剂 (iSRL) 对于巨可能会引起副作用,需要频繁的诊所访问. 新的口服体内静止素受体配体 (oSRL) 为改善患者生活质量提供了一个有希望的替代方案.
科学领域:
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 巨症的治疗已经取得了进展,使得大多数患者能够对生长激素 (GH) 和胰岛素类生长因子-I (IGF-I) 的生化控制.
- 尽管有生物化学控制,但许多壮症患者报告生活质量下降,这可能与当前的治疗方法有关.
- 可注射的长效体静止素受体配体 (iSRL) 是有效的,但与管理挑战和副作用有关.
研究的目的:
- 评估口服索马托斯坦素受体连接体 (oSRL) 配方作为在壮症治疗中对iSRL的潜在替代品.
- 通过克服iSRL的局限性,探索oSRL提高患者生活质量的潜力.
主要方法:
- 临床研究对口服的八二胺囊和paltusotine的综述.
- 对有关oSRL的疗效,安全性和患者报告结果的数据进行分析.
主要成果:
- 口服索马托斯坦素受体配体 (oSRL) 在临床研究中显示出有希望的结果.
- oSRL配方可能为iSRL提供了一个更方便和潜在的更好耐受的替代品.
结论:
- 口服索马托斯坦素受体连接体 (oSRL) 代表了壮症治疗的重大发展.
- 进一步的研究和oSRL的临床采用可以提高患者的管理和生活质量.
相关概念视频
Glucagon-like Receptor Agonists
297
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
297
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Transducer Mechanism: Enzyme-Linked Receptors
2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.3K
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
208
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
208
Drug-Receptor Interaction: Agonist
2.3K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.3K
Oral Hypoglycemic Agents: Glinides
136
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
136


![Microwave-assisted One-pot Synthesis of N-succinimidyl-4-[18F]fluorobenzoate [18F]SFB](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F2755.jpg&w=3840&q=50)